NDA Partners Chairman Carl Peck, MD, announced today that Diane Jorkasky, MD, FACP, an internationally recognized drug development scientist and healthcare executive with global medical and scientific leadership experience in the pharmaceutical and academic healthcare industries, has joined the firm as an Expert Consultant.
ROCHELLE, VA. (PRWEB) DECEMBER 11, 2019
NDA Partners Chairman Carl Peck, MD, announced today that Diane Jorkasky, MD, FACP, an internationally recognized clinical pharmacologist, drug development scientist, and healthcare executive with global medical and scientific leadership experience in the pharmaceutical and academic healthcare industries, has joined the firm as an Expert Consultant. Dr. Jorkasky has held executive leadership positions in drug research and development across therapeutic areas including small molecules, biologics, and novel therapeutic technologies.
Dr. Jorkasky was formerly Executive Vice President, Chief Medical Officer, and Head of Development at Complexa Inc. Prior to this, she served in senior leadership roles at Pfizer as Vice President of Development, Head of Worldwide Clinical Research Operations, Global Leader Clinical Pharmacology and Clinical Research Units, Global Clinical Sciences Leader, and Vice President of Clinical Sciences. In an earlier role, she served as Vice President and Director of Clinical Pharmacology at SmithKline Beecham Pharmaceuticals. She has also served as a member of Scientific Advisory Boards and Board of Directors. In addition to her industry roles, she is a co-curriculum Director and Executive Committee Member for the American Course on Drug Development & Regulatory Science (ACDRS) at the University of California, San Francisco. She is board certified in internal medicine, nephrology, and clinical pharmacology.
“Dr. Jorkasky’s clinical pharmacology expertise and global medical and scientific leadership experience in the pharmaceutical and academic healthcare industries will bring great value to our clients who are developing therapies including small molecules, biologics, and novel therapeutic technologies,” said Dr. Peck. “We are pleased to welcome her to NDA Partners.”
Dr. Jorkasky earned her medical degree from the University of Pennsylvania School of Medicine, conducted her residency in internal medicine at the Pennsylvania Hospital in Philadelphia, and completed her post-doctoral fellowship in nephrology at the Hospital of the University of Pennsylvania. She has published over 100 peer-reviewed articles and teaches internationally on drug development with a particular interest in innovative and quantitative approaches to clinical development strategy.
About NDA Partners
NDA Partners is a life sciences management consulting and contract development organization (CDO) focused on providing product development and regulatory services to the pharmaceutical, biotechnology, and medical device industries worldwide. The highly experienced Principals and Expert Consultants in NDA Partners include three former FDA Center Directors; the former Chairman of the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK; the former Chief Executive Officer and Chief Science Officer at the United States Pharmacopeial Convention (USP); an international team of more than 100 former pharmaceutical industry and regulatory agency senior executives; and an extensive roster of highly proficient experts in specialized areas including nonclinical development, toxicology, pharmacokinetics, CMC, medical device design control and quality systems, clinical development, regulatory submissions, and development program management. Services include product development and regulatory strategy, expert consulting, high-impact project teams, and contract management of client product development programs.
Contact
Earle Martin, Chief Executive Officer
Office: 540-738-2550
[email protected]
Dr. Jorkasky’s global medical and scientific leadership experience in the pharmaceutical and academic healthcare industries will bring great value to our clients who are developing therapies including small molecules, biologics, and novel therapeutic technologies
